CoChat

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation

Open access

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Background: Linaclotide, a guanylate cyclase C agonist, has been shown in clinical trials to improve symptoms of irritable bowel syndrome with constipation (IBS-C). Here we report data from a real-world study of linaclotide in the UK. Methods: This 1-year, multicentre, prospective, observational study in the UK enrolled patients aged 18 years and over initiating linaclotide for IBS-C. The primary assessment was change from baseline in IBS Symptom Severity Scale (IBS-SSS) score at 12 weeks, assessed in patients with paired baseline and 12-week data. Change from baseline in IBS-SSS score at 52 weeks was a secondary assessment. Adverse events were recorded. Results: In total, 202 patients were enrolled: 185 (91.6%) were female, median age was 44.9 years (range 18.1–77.2) and 84 (41.6%) reported baseline laxative use. Mean (standard deviation) baseline IBS-SSS score was 339 (92), with most patients ( n = 129; 66.8%) classified as having severe disease (score ⩾300). In patients with paired data, there was a significant mean (95% confidence interval) decrease in IBS-SSS score from baseline to 12 weeks [−77.0 (−96.3, −57.7); p < 0.001; n = 124] and baseline to 52 weeks [−70.7 (−95.0, −46.5); p < 0.001; n = 76]. Overall, 174 adverse events were reported in 77 (38.1%) patients, most commonly diarrhoea ( n = 54; 26.7%), abdominal pain ( n = 21; 10.4%) and abdominal distension ( n = 13; 6.4%). Conclusion: Linaclotide significantly improved IBS-SSS score at 12 and 52 weeks. These results provide insights into outcomes with linaclotide treatment over 1 year in patients with IBS-C in real-world clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1756284818798791

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Participant flow. IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale.
Figure 1. Participant flow. IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale.CC BY-NC · PubMed Central
Figure 2. Change in IBS-SSS score in the overall population and by baseline severity at 12 weeks (a) and 52 weeks (b). aScored from 0 to 500; bincludes six patients with IBS-C classified as mild at baseline; cincludes four patients with IBS-C classified as mild at baseline. IBS-C, irritable bowel syndrome with constipation; IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale; SD, standard deviation.
Figure 2. Change in IBS-SSS score in the overall population and by baseline severity at 12 weeks (a) and 52 weeks (b). aScored from 0 to 500; bincludes six patients with IBS-C classified as mild at baseline; cincludes four patients with IBS-C classified as mild at baseline. IBS-C, irritable bowel syndrome with constipation; IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale; SD, standard deviation.CC BY-NC · PubMed Central
Figure 3. Change in IBS-SSS score at 52 weeks in patients continuing or discontinuing linaclotide. aScored from 0 to 500. IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale.
Figure 3. Change in IBS-SSS score at 52 weeks in patients continuing or discontinuing linaclotide. aScored from 0 to 500. IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale.CC BY-NC · PubMed Central
Figure 4. Response to linaclotide in the overall population and by baseline severity at 12 weeks (a) and 52 weeks (b). Response to linaclotide was defined as a reduction in IBS-SSS overall score of ⩾50, or a reduction in score to <150 for patients with a baseline score of ⩾150. aIncludes six patients with IBS-C classified as mild at baseline; bincludes four patients with IBS-C classified as mild at baseline. IBS-C, irritable bowel syndrome with constipation; IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale.
Figure 4. Response to linaclotide in the overall population and by baseline severity at 12 weeks (a) and 52 weeks (b). Response to linaclotide was defined as a reduction in IBS-SSS overall score of ⩾50, or a reduction in score to <150 for patients with a baseline score of ⩾150. aIncludes six patients with IBS-C classified as mild at baseline; bincludes four patients with IBS-C classified as mild at baseline. IBS-C, irritable bowel syndrome with constipation; IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale.CC BY-NC · PubMed Central
Figure 5. IBS-QOL overall score at 12 and 52 weeks (a) and change from baseline in IBS-QOL overall score and domain scores at 12 and 52 weeks (b). aScored from 0 to 100 (higher scores indicate better functioning). *p < 0.05; **p < 0.01; ***p < 0.001. CI, confidence interval; IBS-QOL, Irritable Bowel Syndrome Quality of Life; SD, standard deviation.
Figure 5. IBS-QOL overall score at 12 and 52 weeks (a) and change from baseline in IBS-QOL overall score and domain scores at 12 and 52 weeks (b). aScored from 0 to 100 (higher scores indicate better functioning). *p < 0.05; **p < 0.01; ***p < 0.001. CI, confidence interval; IBS-QOL, Irritable Bowel Syndrome Quality of Life; SD, standard deviation.CC BY-NC · PubMed Central
Figure 6. EQ-5D index overall score at 12 and 52 weeks (a) and EQ-VAS score at 12 and 52 weeks (b). aScored from 0 to 1 (1 indicates full health); bscored from 0 to 100 (higher scores indicate better health state). EQ-5D, EuroQol five dimension; EQ-VAS, EuroQol visual analogue scale; SD, standard deviation.
Figure 6. EQ-5D index overall score at 12 and 52 weeks (a) and EQ-VAS score at 12 and 52 weeks (b). aScored from 0 to 1 (1 indicates full health); bscored from 0 to 100 (higher scores indicate better health state). EQ-5D, EuroQol five dimension; EQ-VAS, EuroQol visual analogue scale; SD, standard deviation.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Emmanuel A, 2016, United European Gastroenterol J, 4, A295

Cited by

See all 12

Metadata

Authors
Yiannakou, Y., Agrawal, A., Allen, P. B., Arebi, N., Brown, S. R., Eugenicos, M. P., Farmer, A. D., McLain-Smith, S., McLaughlin, J., Sanders, D. S., Lawrance, D., & Emmanuel, A.
Affiliations
  • County Durham and Darlington NHS Foundation Trust (GB)
  • Doncaster Royal Infirmary (GB)
  • South Eastern Health and Social Care Trust (GB)
  • London North West Healthcare NHS Trust (GB)
  • Sheffield Teaching Hospitals NHS Foundation Trust (GB)
  • NHS Lothian (GB)
  • University Hospitals of North Midlands NHS Trust (GB)
  • pH Associates Ltd, Marlow, UK
  • Manchester Academic Health Science Centre (GB)
  • Allergan (United Kingdom) (GB)
  • University College Hospital (GB)
Corresponding author
Yiannakou, Yan
Venue
Therapeutic Advances in Gastroenterology
Published
2018-01
Volume
11
Pages
1756284818798791-1756284818798791
ISSN
  • 1756-283X (ISSN-L)
  • 1756-2848
OpenAlex
W2894886573
Cited by
12
References
32
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 1
FWCI
0.95
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Therapeutic Advances in Gastroenterology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, cc-by-nc)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Spiral (Imperial College London) (submittedVersion)
Funders
Allergan plc.
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
Keywords
linaclotide, irritable bowel syndrome with constipation, guanylate cyclase-C agonist, symptom severity, real-world outcomes, adverse events, diarrhea, laxative use, long-term treatment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. https://app.cochat.ai/papers/10.1177/1756284818798791
The paper
Yiannakou, Y., Agrawal, A., Allen, P. B., Arebi, N., Brown, S. R., Eugenicos, M. P., Farmer, A. D., McLain-Smith, S., McLaughlin, J., Sanders, D. S., Lawrance, D., & Emmanuel, A. (2018). UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation. Therapeutic Advances in Gastroenterology. https://doi.org/10.1177/1756284818798791

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.